Lyell Immunopharma, Inc. 8-K

What Happened

• Lyell Immunopharma, Inc. filed a Form 8-K on March 12, 2026 (Item 2.02) to announce that it issued a press release reporting its financial results for the quarter and full year ended December 31, 2025. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: March 12, 2026 (Form 8-K, Item 2.02).
• Reporting periods: quarter and full year ended December 31, 2025.
• Press release containing the results is included as Exhibit 99.1 to the 8-K.
• The 8-K was signed by Mark Meltz, General Counsel and Corporate Secretary.

Why It Matters

• This filing is the company’s formal, timely disclosure that its quarterly and full-year 2025 financial results have been released; investors should review the attached press release for the specific revenue, profit/loss, cash position, and any management commentary or guidance.
• Because the 8-K itself references the press release rather than listing financial line items in the filing text, retail investors should read the Exhibit 99.1 press release and any subsequent SEC filings (e.g., 10-K) for the detailed figures that could affect valuation or near-term trading decisions.